FDA Approves Durvalumab as First Perioperative Immunotherapy for Gastric and GEJ Cancers

FDA Approves Keytruda–Padcev Combination as First Perioperative Treatment for Bladder Cancer

Sevabertinib Wins FDA Approval with Strong Responses in HER2-Mutated NSC Lung Cancer

FDA Approves Epcoritamab-bysp as the First Bispecific Antibody for Follicular Lymphoma

FDA Approves Ziftomenib as a New Targeted Option for NPM1+ Acute Myeloid Leukemia

Radioligand Therapy Pluvicto Reduces Progression Risk by 28% in mHS Prostate Cancer

Lenvatinib Plus Everolimus Improves Outcomes After PD-1 Failure in Kidney Cancer

Novartis Invests $23 Billion to Boost Radioligand Manufacturing Capacity in Carlsbad

Ribociclib Extends Disease-Free Survival Beyond Treatment in HR+/HER2– Early Breast Cancer

DeLLphi-303: Tarlatamab Plus Chemo Achieves 71% Response in ES Small-Cell Lung Cancer

ctDNA Blood Test Guides Chemotherapy Decisions for Tailored Colon Cancer Treatment

Trodelvy Emerges as Potential New Standard for First-Line Metastatic TN Breast Cancer

Datroway Extends Survival by 5 Months in Metastatic Triple-Negative Breast Cancer

Lenvatinib Plus Pembrolizumab Delivers Durable 5-Year Survival in Endometrial Carcinoma

Reprogramming Cancer Cell Death: A New Immune-Based Strategy for Blood Cancers

In Vivo CAR T on the Horizon: BMS Acquires Orbital to Expand Cell Therapy Reach

AstraZeneca makes deal with Trump Admin to Cut Drug Prices 80% and Invest $50B in US

FDA Approves Libtayo as First Adjuvant Immunotherapy for High-Risk CS Cell Carcinoma

Datroway Improves Survival in First-Line Treatment of Metastatic Triple- Breast Cancer

FDA Approves Tecentriq–Zepzelca Combo as FL Maintenance Therapy for ES-SC Lung Cancer

FDA Approves Imlunestrant for ESR1-Mutated Metastatic Breast Cancer

DESTINY-Breast05: Enhertu Outperforms T-DM1 in High-Risk HER2+ Early Breast Cancer

Giredestrant Plus Everolimus Improves PF Survival in ER+ Advanced Breast Cancer

EMA’s CHMP Backs Subcutaneous Pembrolizumab in Head and Neck Cancer

FDA Grants Breakthrough Status to Raludotatug Deruxtecan for Refractory Ovarian Cancer

GSK to invest $30 billion in R&D and Manufacturing in the US over next 5 years

Climate-Driven Health Risks to Put $1.5 Trillion in Productivity at Stake by 2050

CVC and V Foundation Fuel $500K Grant for Next Phase of Breast Cancer Vaccine Research

TROPION-Breast01: Redefining Treatment for HR+/HER2– Metastatic Breast Cancer

ONCOLife’s New Edition Is Live with Breakthroughs in Cancer Research

FDA Grants Breakthrough Status to Izalontamab Brengitecan for EGF+ Lung Cancer

The First FDA-Cleared Blood Test for Alzheimer’s Diagnosis Now Available on the Market

First Patient Enrolled for Aliya® PEF Tumor Ablation of Lung/Liver Soft-Tissue Lesions

FDA Grants Accelerated Approval to Semaglutide for MASH with Liver Fibrosis

mRNA Vaccines Plus Checkpoint Inhibitors Shows Curative Potential in Gastric Cancer

FDA Approves Papzimeos, First Immunotherapy for Recurrent Respiratory Papillomatosis

Breaking the Molecular Link Between Alcohol and Pancreatic Cancer by Targeting CREB

PADCEV–KEYTRUDA Combination Delivers Survival Gains in High-Risk Bladder Cancer

FDA Grants Fast Track Designation to Birelentinib for Relapsed/Refractory CLL and SLL

Epcoritamab + R2 Achieves 95.7% ORR, Cuts Risk by 79% in R/R Follicular Lymphoma

Zongertinib Gains FDA Accelerated Approval for HER2+ NSCLC with 75% ORR

Novel Viral Immunotherapy SuperNova Gains FDA Fast Track Designation for Sarcoma

FDA Fast-Tracks Breyanzi as First CAR T Cell Therapy for Marginal Zone Lymphoma

FDA Approves Modeyso as First-Ever Therapy for Pediatric Brain Tumor, H3 K27M+ Glioma

2025 Pan-Mass Challenge Draws Thousands of Cyclists to Fuel Next Era of Cancer Research

Targeting eIF2A to Halt Melanoma: Study Reveals Key Driver of Cancer Cell Migration

Promising Results: Jaypirca Outperforms Imbruvica in Landmark Phase 3 CLL/SLL Trial

Artificial Sweetener Sucralose May Undermine Cancer Immunotherapy, Study Finds

First Non-Invasive Endometrial Cancer Detection Test, EdenDx, Launched by Gnosis

EMA Grants Orphan Drug Designation to Nuvisertib for Rare Blood Cancer Myelofibrosis